---
document_datetime: 2025-09-17 10:11:53
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0105465
conversion_datetime: 2025-12-27 19:28:21.282436
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ELREXFIO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 11/09/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | PL   | EMA/VR/0000278463   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|---------------------|
| Variation type II / EMA/VR/0000280555 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance orchangeinthemanufacturer (includingwhererelevantquality control testing sites)of the active substance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.j Changes to qualitycontroltesting arrangementsfora biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted | 04/09/2025 | N/A |      |                     |
| Variation type IB / EMA/VR/0000285949 | This was an application for a group of variations. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.II.f.1.bExtension of the shelf life of the finishedproduct-B.II.f.1.b.5Extension of the shelf-life of a biological/ immunological medicinalproductinaccordancewith an                                                                                                                                                                                     | 21/07/2025 |     | SmPC |                     |

<div style=\"page-break-after: always\"></div>

|                                       | approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |             |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-------------------|
| Variation type IB /                   | B.II.f.1.bExtensionof the shelf lifeof the finished product-B.II.f.1.b.2After first opening (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                 | 04/04/2025 |     | SmPC and PL | EMA/VR/0000246959 |
| Variation type IA / EMA/VR/0000237706 | A.ADMINISTRATIVE CHANGES-A.4 Change inthenameand/oraddressof:a manufacturer(including whererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material,reagent orintermediate usedinthemanufactureof the active substance (where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 06/03/2025 | N/A |             |                   |